About The Study: The results of this study suggest that the BNT162b2 XBB vaccine (Pfizer-BioNTech) provided protection against COVID-19–associated hospitalization and emergency department or urgent care visits among children 5 to 17 years of age during the 2023-2024 season with estimated vaccine effectiveness point estimates ranging from 63% to 73%.
Corresponding Author: To contact the corresponding author, Sara Y. Tartof, PhD, MPH, email Sara.Y.Tartof@kp.org .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2024.49944)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.49944?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=121224
About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.
JAMA Network Open